Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.

Masahiro Tsuboi; Harubumi Kato; Kanji Nagai; Ryosuke Tsuchiya; Hiromi Wada; Hirohito Tada; Yukito Ichinose; Masahiro Fukuoka; Haiyi Jiang

doi:10.1097/00001813-200511000-00012

Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.

Identifier:nobleid.org/w1/20260515/9482CEEB

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/9482CEEB.svg?ark=w1%2F20260515%2F9482CEEB)](https://nobleid.org/work/w1/20260515/9482CEEB)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.

Identifier:nobleid.org/w1/20260515/9482CEEB

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/9482CEEB.svg?ark=w1%2F20260515%2F9482CEEB)](https://nobleid.org/work/w1/20260515/9482CEEB)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work